Estimated direct costs of non‐small cell lung cancer by stage at diagnosis and disease management phase: A whole‐disease model

Non‐small cell lung cancer (NSCLC) is the first cause of cancer‐related death among men and the second among women worldwide. It also poses an economic threat to the sustainability of healthcare services. This study estimated the direct costs of care for patients with NSCLC by stage at diagnosis, and management phase of pathway recommended in local and international guidelines.

[1]  R. Wood,et al.  Cost burden associated with advanced non-small cell lung cancer in Europe and influence of disease stage , 2019, BMC Cancer.

[2]  Rebecca A Miksad,et al.  Real-World Outcomes of Patients with Metastatic Non-Small Cell Lung Cancer Treated with Programmed Cell Death Protein 1 Inhibitors in the Year Following U.S. Regulatory Approval. , 2018, The oncologist.

[3]  C. Kong,et al.  Lung cancer costs by treatment strategy and phase of care among patients enrolled in Medicare , 2018, Cancer medicine.

[4]  M. Marangolo,et al.  [Facts and figures of clinical pathways in Italy: results from the PDTA Net project.] , 2019, Recenti progressi in medicina.

[5]  黄柳.  Updates in Version 2.2019 of the NCCN Guidelines for Non-Small Cell Lung Cancer from Version 1.2019 include , 2019 .

[6]  B. Feinberg,et al.  Understanding total cost of care in advanced non-small cell lung cancer pre- and postapproval of immuno-oncology therapies. , 2018, The American journal of managed care.

[7]  C. Vallejos,et al.  The burden of lung cancer in Latin-America and challenges in the access to genomic profiling, immunotherapy and targeted treatments. , 2018, Lung cancer.

[8]  D. Planchard,et al.  Durvalumab in non-small-cell lung cancer patients: current developments. , 2018, Future oncology.

[9]  Ying Cheng,et al.  Osimertinib in Untreated EGFR‐Mutated Advanced Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[10]  R. Jagsi,et al.  Patterns of Treatment and Outcomes for Definitive Therapy of Early Stage Non-Small Cell Lung Cancer. , 2017, The Annals of thoracic surgery.

[11]  Witold Rzyman,et al.  European position statement on lung cancer screening. , 2017, The Lancet. Oncology.

[12]  E. Felip,et al.  Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057). , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Tarek Mekhail,et al.  Durvalumab after Chemoradiotherapy in Stage III Non–Small‐Cell Lung Cancer , 2017, The New England journal of medicine.

[14]  Ping Yang,et al.  Survival in Surgical and Nonsurgical Patients With Superior Sulcus Tumors. , 2017, The Annals of thoracic surgery.

[15]  B. Döme,et al.  Trimodality therapy for Pancoast tumors: T4 is not a contraindication to radical surgery , 2017, Journal of surgical oncology.

[16]  Iaslc Staging,et al.  The IASLC Lung Cancer Staging Project: External Validation of the Revision of the TNM Stage Groupings in the Eighth Edition of the TNM Classification of Lung Cancer , 2017 .

[17]  Rafal Dziadziuszko,et al.  Alectinib versus Crizotinib in Untreated ALK‐Positive Non–Small‐Cell Lung Cancer , 2017, The New England journal of medicine.

[18]  M. Janssen-Heijnen,et al.  Trends in treatment and relative survival among Non-Small Cell Lung Cancer patients in the Netherlands (1990-2014): Disparities between younger and older patients. , 2017, Lung cancer.

[19]  M. Casiraghi,et al.  Surgical Treatment of Superior Sulcus Tumors: A 15-Year Single-center Experience. , 2017, Seminars in thoracic and cardiovascular surgery.

[20]  Carlos Barrios,et al.  Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial , 2017, The Lancet.

[21]  A. Fairchild,et al.  Radiation-induced esophagitis in lung cancer , 2016, Lung Cancer.

[22]  Y. Shentu,et al.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.

[23]  J. Crowley,et al.  The IASLC Lung Cancer Staging Project: Methodology and Validation Used in the Development of Proposals for Revision of the Stage Classification of NSCLC in the Forthcoming (Eighth) Edition of the TNM Classification of Lung Cancer , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[24]  Parminder Raina,et al.  Screening for lung cancer: A systematic review and meta-analysis. , 2016, Preventive medicine.

[25]  B Rachet,et al.  Deriving stage at diagnosis from multiple population-based sources: colorectal and lung cancer in England , 2016, British Journal of Cancer.

[26]  A. Rossi,et al.  Anti PD-1 and PDL-1 Immunotherapy in the Treatment of Advanced Non- Small Cell Lung Cancer (NSCLC): A Review on Toxicity Profile and its Management. , 2016, Current drug safety.

[27]  J. Niland,et al.  Variation in Definitive Therapy for Localized Non-Small Cell Lung Cancer Among National Comprehensive Cancer Network Institutions. , 2016, International journal of radiation oncology, biology, physics.

[28]  H. Groen,et al.  Costs of non-small cell lung cancer in the Netherlands. , 2016, Lung cancer.

[29]  A. Jemal,et al.  Lung Cancer Statistics. , 2016, Advances in experimental medicine and biology.

[30]  K. Jöckel,et al.  Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE). , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Reiner Leidl,et al.  Cost-components of lung cancer care within the first three years after initial diagnosis in context of different treatment regimens. , 2015, Lung cancer.

[32]  J. Warren,et al.  An international comparison of costs of end-of-life care for advanced lung cancer patients using health administrative data , 2015, Palliative medicine.

[33]  I. Olver,et al.  The financial hazard of personalized medicine and supportive care , 2015, Supportive Care in Cancer.

[34]  Ronald C. Chen,et al.  Unanticipated hospital admissions during or soon after radiation therapy: Incidence and predictive factors. , 2015, Practical radiation oncology.

[35]  F. Kwiatkowski,et al.  Combined treatment modalities in Pancoast tumor: results of a monocentric retrospective study. , 2015, Chinese clinical oncology.

[36]  A. Mcguire,et al.  Treatment cost of non-small cell lung cancer in three European countries: comparisons across France, Germany, and England using administrative databases , 2015, Journal of medical economics.

[37]  Julieta Corral,et al.  Estimation of lung cancer diagnosis and treatment costs based on a patient-level analysis in Catalonia (Spain) , 2015, BMC Health Services Research.

[38]  H. Cohen,et al.  Generalizability of trial results to elderly Medicare patients with advanced solid tumors (Alliance 70802). , 2015, Journal of the National Cancer Institute.

[39]  F. Cappuzzo,et al.  First-line crizotinib versus chemotherapy in ALK-positive lung cancer. , 2014, The New England journal of medicine.

[40]  V. Rogalewicz,et al.  The costs and reimbursements for lung cancer treatment among selected health care providers in the Czech Republic , 2014 .

[41]  Ioanna Kougioumtzi,et al.  Pancoast tumors: characteristics and preoperative assessment. , 2014, Journal of thoracic disease.

[42]  C. Peschel,et al.  The impact of chemotherapy-induced side effects on medical care usage and cost in German hospital care — an observational analysis on non-small-cell lung cancer patients , 2013, Supportive Care in Cancer.

[43]  Hazel Squires,et al.  Whole disease modeling to inform resource allocation decisions in cancer: a methodological framework. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[44]  G. Apolone,et al.  Surgery for oligometastatic non-small cell lung cancer: long-term results from a single center experience. , 2012, The Journal of thoracic and cardiovascular surgery.

[45]  S. Tyldesley,et al.  Stage III Non–Small-Cell Lung Cancer: Population-Based Patterns of Treatment in British Columbia, Canada , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[46]  Yan Sun,et al.  Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. , 2012, The Lancet. Oncology.

[47]  C. Earle,et al.  Lung cancer treatment costs, including patient responsibility, by disease stage and treatment modality, 1992 to 2003. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[48]  V. Young,et al.  Treatment of pancoast tumors from the surgeons prospective: re-appraisal of the anterior-manubrial sternal approach , 2010, Journal of cardiothoracic surgery.

[49]  Thomas Rotter,et al.  Clinical pathways: effects on professional practice, patient outcomes, length of stay and hospital costs. , 2010, The Cochrane database of systematic reviews.

[50]  R. Govindan,et al.  Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[51]  L. Gaspar,et al.  National survey of non-small cell lung cancer in the United States: epidemiology, pathology and patterns of care. , 2007, Lung cancer.

[52]  Randall K Ten Haken,et al.  Final toxicity results of a radiation-dose escalation study in patients with non-small-cell lung cancer (NSCLC): predictors for radiation pneumonitis and fibrosis. , 2006, International journal of radiation oncology, biology, physics.

[53]  V. Rusch,et al.  Morbidity and mortality of major pulmonary resections in patients with early-stage lung cancer: initial results of the randomized, prospective ACOSOG Z0030 trial. , 2006, The Annals of thoracic surgery.

[54]  Avraham Eisbruch,et al.  Non-small cell lung cancer therapy-related pulmonary toxicity: an update on radiation pneumonitis and fibrosis. , 2005, Seminars in oncology.

[55]  Murray Turoff,et al.  The Delphi Method: Techniques and Applications , 1976 .

[56]  Marianne Farningram Hearn.  The Burden , 1927 .